Literature DB >> 30218194

The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.

Hussein Khaled1, Heba Gamal2, Mohamed Lotayef3, Michael Knauer4, Beat Thürliman4.   

Abstract

PURPOSE: The theme of the 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria was about seeking where appropriate to escalate or de-escalate therapies for early breast cancer based on the up-to-date information of loco-regional and systemic therapies. Along with this line, a group of Egyptian experts decided to arrange for a consensus session to elicit the differences and similarities in therapy recommendations for early breast cancer in Egypt compared to the original Saint Gallen voting and recommendations.
METHODS: During the Egyptian National Cancer Institute's Annual Congress held in November 2017, 30 Egyptian scientists and clinicians from different specialties gathered in a special session and voted on the same questions of the original 15th St. Gallen consensus. Therapies were discussed from different aspects including their intensity, duration, and side effects, and were correlated with tumor stage and tumor biology. RESULTS AND
CONCLUSIONS: This report summarizes the voting questions and resulting percentages of answers of the Egyptian scientists. Interestingly the differences were minimal between the Cairo and original Saint Gallen Consensus denoting a more global view of breast cancer management all over the world.

Entities:  

Keywords:  Adjuvant therapy; Breast cancer; Egypt

Mesh:

Year:  2018        PMID: 30218194     DOI: 10.1007/s10549-018-4945-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  1 in total

1.  The MS-lincRNA landscape reveals a novel lincRNA BCLIN25 that contributes to tumorigenesis by upregulating ERBB2 expression via epigenetic modification and RNA-RNA interactions in breast cancer.

Authors:  Shouping Xu; Hongbo Liu; Lin Wan; Weijia Zhang; Qin Wang; Shumei Zhang; Shipeng Shang; Yan Zhang; Da Pang
Journal:  Cell Death Dis       Date:  2019-12-04       Impact factor: 8.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.